论文部分内容阅读
肾细胞癌被认为是最难治的恶性肿瘤之一。由于对肾细胞癌分子发病机制研究的进一步深入,在晚期肾细胞的治疗中出现了一系列成功范例。在过去20年,非特异性免疫治疗被认为是晚期肾细胞癌治疗标准。近年,随着分子靶向药物的研发和临床使用,肿瘤的分子靶向治疗已成为肿瘤治疗的研究热点,同时由于对肾细胞癌进一步了解,肾细胞癌的治疗已开始转向抗-血管内皮生长因子及其相关通路研究,大量的临床研究试验,证明了分子靶向治疗在晚期肾细胞癌的疗效,其中Sorafenib(索拉非尼)和Sunitinib(舒尼替尼)分别于2005年和2006年经美国FDA批准用于晚期肾细胞癌。本文将围绕VEGF在肾细胞癌的重要性和Bevacizumab(贝伐单抗)、Sunitinib和So-rafenib治疗晚期肾细胞癌研究进展等问题进行简要阐述。
Renal cell carcinoma is considered as one of the most refractory malignancies. Due to the further study of the pathogenesis of renal cell carcinoma, a series of successful examples have emerged in the treatment of advanced renal cells. In the past 20 years, non-specific immunotherapy is considered the treatment of advanced renal cell carcinoma. In recent years, with the development and clinical application of molecular targeted drugs, molecular targeted therapy of tumors has become a research hotspot in cancer treatment. Meanwhile, due to further understanding of renal cell carcinoma, treatment of renal cell carcinoma has begun to turn to anti-vascular endothelial growth Factors and their related pathways, a large number of clinical studies, proved the efficacy of molecular targeted therapy in advanced renal cell carcinoma, Sorafenib (Sorafenib) and Sunitinib (Sunitinib) were in 2005 and 2006 Approved by the U.S. FDA for advanced renal cell carcinoma. This article will focus on the importance of VEGF in renal cell carcinoma and Bevacizumab (bevacizumab), Sunitinib and So-rafenib treatment of advanced renal cell carcinoma and other issues are briefly described.